HANSOH PHARMA News

Hanson Pharmaceuticals (3692.HK): Independent R&D and BD cooperation drive steady growth in the company's performance

華興證券Apr 3 00:00

Bank Rating | Citibank: Raising Hanson Pharmaceuticals Target Price to HK$28 to Maintain “Buy” Rating

Gelonghui FinanceMar 29 16:48

Hanson Pharmaceuticals (3692.HK): Innovative drugs will lead steady revenue growth

中泰國際Mar 28 19:36

Citibank: Maintaining Hanson Pharmaceuticals (03692)'s “Buy” Rating and Raising the Target Price to HK$28

Zhitong FinanceMar 28 16:54

CICC: Maintaining Hanson Pharmaceuticals' (03692) “outperforming the industry” rating, the target price was raised to HK$17.81

Zhitong FinanceMar 28 09:20

Hanson Pharmaceuticals (03692.HK): Innovative drug revenue share increased, ADC pipeline promoted globally

中金公司Mar 28 07:46

Hanson Pharmaceuticals (03692.HK): High performance, innovation and international implementation drive new growth

廣發證券Mar 28 00:00

Hanson Pharmaceuticals (3692.HK): FY23 exceeds expectations, FY24 Amelot drives product revenue growth to fix and raise target prices

交銀國際Mar 27 20:41

HANSOH PHARMACEUTICAL(3692.HK):2023 RESULTS BEAT ON AMEILE AND COLLABORATION REVENUE; DOUBLEDIGIT DRUG SALES GROWTH IN 2024; UPGRADE TO BUY

中银国际Mar 27 15:56

BOC International: Maintaining Hanson Pharmaceuticals (03692)'s “Neutral” Rating Target Price of HK$16

Zhitong FinanceMar 27 14:26

Hanson Pharmaceuticals (03692.HK): Innovative drug revenue share reached a new high, ADC project authorized to go overseas

招商證券Mar 27 14:31

Nomura Downgrades Hansoh Pharmaceutical to Neutral From Buy, Adjusts Price Target to HK$15.03 From HK$13.01

MT NewswiresMar 14 15:59

Nomura: Downgrade Hanson Pharmaceuticals (03692) rating to “hold” and increase target price to HK$15.03

Zhitong FinanceMar 14 14:11

China Thailand International: Adjust Hanson Pharmaceuticals (03692) rating to “increase holdings” and raise the target price to HK$16.7

Zhitong FinanceJan 5 09:31

Bank Ratings｜Goldman Sachs: Yu Hanson Pharmaceutical's “buy” rating target price of HK$16.86

Gelonghui FinanceDec 25, 2023 09:40

Goldman Sachs: Yu Hanson Pharmaceuticals (03692) “buy” rating target price of HK$16.86

Zhitong FinanceDec 21, 2023 14:18

Hanson Pharmaceuticals (03692.HK): Innovation drives leading pharmaceutical development to a new level

廣發證券Dec 12, 2023 00:00

Hanson Pharmaceuticals (3692.HK): The results of the new target layout are gradually showing

華興證券Oct 26, 2023 00:00

Hanson Pharmaceuticals (03692.HK): The value of the pipeline from simulation to innovation is highly flexible

華創證券Oct 23, 2023 11:46

Hanson Pharmaceuticals (03692.HK): B7-H4ADC authorizes GSK over 10 billion yuan

國金證券Oct 21, 2023 00:00